Ostia Sciences Inc.
$30,000.00 CAD
≈ 5 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- November 3, 2025 – August 3, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q3-1037036
Published purpose
The youth will support Ostia’s translational research and clinical development programs for S. salivarius SALI-10®, a next-generation oral probiotic producing novel phosphorylated lantibiotics. This work will contribute to a key clinical trial evaluating SALI-10’s ability to reduce gingivitis and prevent dysbiosis in otherwise healthy individuals. This work also underpins Ostia’s regulatory filings with Health Canada (NHP, Class III NPN) and the US FDA GRAS pathway, advancing the company’s commercialization strategy.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions